866-997-4948(US-Canada Toll Free)

Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48)-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Sep 2017

Category :

Pharmaceutical

No. of Pages : 54 Pages

Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48)-Pipeline Review, H2 2017

Summary

Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48)-Tyrosine-protein phosphatase non-receptor type 1 also known as protein-tyrosine phosphatase 1B (PTP1B) is an enzyme encoded by the PTPN1 gene. It acts as a regulator of endoplasmic reticulum unfolded protein response. It plays an important role in CKII- and p60c-src-induced signal transduction cascades. It regulates the EFNA5-EPHA3 signaling pathway which modulates cell reorganization and cell-cell repulsion. It mediates dephosphorylation of EIF2AK3/PERK, inactivating the protein kinase activity of EIF2AK3/PERK. It regulates the hepatocyte growth factor receptor signaling pathway through dephosphorylation of MET.

Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) pipeline Target constitutes close to 15 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 4 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Oncology, Central Nervous System and Undisclosed which include indications Type 2 Diabetes, Obesity, Diabetes, Breast Cancer, Metastatic Breast Cancer and Rett Syndrome.

The latest report Tyrosine Protein Phosphatase Non Receptor Type 1-Pipeline Review, H2 2017, outlays comprehensive information on the Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48)
- The report reviews Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48)-Overview 7
Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48)-Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 13
Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48)-Therapeutics Assessment 15
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48)-Companies Involved in Therapeutics Development 20
Aurigene Discovery Technologies Ltd 20
Ionis Pharmaceuticals Inc 20
Warp Drive Bio Inc 20
Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48)-Drug Profiles 22
Antisense Oligonucleotide to Inhibit PTP1B for Type 2 Diabetes-Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
Antisense Oligonucleotide to Inhibit PTP1B for Type 2 Diabetes and Obesity-Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
AU-2439-Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
CPT-157633-Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
DPM-1001-Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
IONISPTP-1BRx-Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
KQ-791-Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
S-009629-Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Small Molecules to Inhibit PTP1B for Diabetes-Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Small Molecules to Inhibit PTP1B for Oncology-Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Small Molecules to Inhibit PTP1b for Oncology-Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecules to Inhibit PTP1B for Type 2 Diabetes and Obesity-Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecules to Inhibit PTP1B for Type 2 Diabetes and Obesity-Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecules to Inhibit PTPB1 for Diabetes-Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
trodusquemine-Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48)-Dormant Products 38
Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48)-Discontinued Products 40
Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48)-Product Development Milestones 41
Featured News & Press Releases 41
Feb 03, 2015: Isis Pharmaceuticals Reports Data From Phase 2 Study of ISIS-PTP1B Rx in Patients With Type 2 Diabetes 41
May 27, 2014: DepYmed Announces Validation of Trodusquemine as a Therapeutic Candidate for HER2-positive Breast Cancer 42
Jul 10, 2013: Local foundation raises $15,000 for breast cancer research at Cold Spring Harbor Laboratory 42
Dec 07, 2012: Isis Pharma Reports Positive Phase I Results Of Metabolic Disorders Drug ISIS-PTP1BRx 43
Sep 29, 2011: Powerful antibody-based strategy suggests a new therapeutic approach to diabetes and obesity 44
Jul 21, 2011: Isis Initiates Phase I Study Of ISIS-PTP1BRx To Treat Type 2 Diabetes 45
Oct 21, 2009: Isis Pharmaceuticals Reports Positive Phase 2 Data For ISIS 113715 In Patients With Type 2 Diabetes 46
Feb 10, 2009: Genaera Presents Preliminary Phase 1b Data For Trodusquemine (MSI-1436) 47
Jan 22, 2009: Genaera Presents Promising Preclinical Data For Trodusquemine (MSI-1436) At Keystone Symposia 48
Dec 01, 2008: Genaera Begins Phase 1b Trial Of Trodusquemine (MSI-1436) In Overweight And Obese Type 2 Diabetics 48
Oct 06, 2008: Genaera Corporation Reports Phase 1 Data For Trodusquemine (MSI-1436) At The North American Association For The Study Of Obesity Annual Meeting 49
Jul 25, 2008: Genaera Releases Phase 1 Data And New Preclinical Data On The CNS Function Of Trodusquemine (MSI-1436) At CBI Obesity Summit 50
Jul 14, 2008: Genaera Corporation Presents Data On Mechanism Of Inhibition Of PTP-1B For Trodusquemine (MSI-1436) At Federation Of American Societies For Experimental Biology (FASEB) Meeting 50
Jun 09, 2008: Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data For Trodusquemine (MSI-1436) At American Diabetes Association 51
Mar 28, 2008: Genaera Corporation Announces MSI-1436 Data Presented At Society Of Neuroscience Meeting 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54

List of Tables
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indication, H2 2017 10
Number of Products under Development by Companies, H2 2017 11
Products under Development by Companies, H2 2017 12
Number of Products under Investigation by Universities/Institutes, H2 2017 13
Products under Investigation by Universities/Institutes, H2 2017 14
Number of Products by Stage and Mechanism of Actions, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 19
Pipeline by Aurigene Discovery Technologies Ltd, H2 2017 20
Pipeline by Ionis Pharmaceuticals Inc, H2 2017 20
Pipeline by Warp Drive Bio Inc, H2 2017 21
Dormant Products, H2 2017 38
Dormant Products, H2 2017 (Contd..1), H2 2017 39
Discontinued Products, H2 2017 40

List of Figures
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Top 10 Indications, H2 2017 10
Number of Products by Stage and Mechanism of Actions, H2 2017 15
Number of Products by Routes of Administration, H2 2017 16
Number of Products by Stage and Routes of Administrations, H2 2017 16
Number of Products by Molecule Types, H2 2017 18
Number of Products by Stage and Molecule Types, H2 2017 18

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *